Skip to content

Insider · CIK 0001831218

Sean Bohen

ceopresidentofficerdirector

Files at OLMA (Olema Pharmaceuticals, Inc.). First filing Dec 11, 2024, latest Dec 11, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $986k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

OLMA: Olema Pharmaceuticals, Inc.

OLMAOct 9, 2026 · close 7.82

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
75Notable
OLMAsell 6
Olema Pharmaceuticals, Inc.
$986k
109,502 shares
-31%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 28, 2025OLMA
Olema Pharmaceuticals, Inc.
AGrant or award
Stock Option (Right to Buy)derivative
+650,000$0.00$0650,000Mar 3, 2025
Dec 9, 2024OLMA
Olema Pharmaceuticals, Inc.
AGrant or award
Common Stock
+204,750$0.00$0351,164Dec 11, 2024
Dec 10, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-52,328$9.37$490k298,836Dec 11, 2024
Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-55,907$8.66$484k242,929Dec 11, 2024
Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
SOpen-market sale
Common Stock
-1,267$9.39$12k241,662Dec 11, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Sean Bohen: insider trades and track record | InsiderTell